TOKYO & NEW YORK & DÜSSELDORF, Germany--(BUSINESS WIRE)--Generating cutting-edge therapeutics requires precision, safety, and efficiency from manufacturing equipment. The next generation of oligo manufacturing, the process of producing short sequences of nucleotides (building blocks of DNA or RNA), innovation from Asahi Kasei Bioprocess (AKB), the THESYS™ ACS ERGO synthesis column, will be on display and demonstrated at Booth 213 at TIDES USA 2024 from May 14th to 17th at the Hynes Convention Center in Boston.

东京、纽约和德国迪塞尔多夫——（商业新闻短讯）——产生尖端疗法需要制造设备的精确性、安全性和效率。下一代寡核苷酸制造，即产生短核苷酸序列（DNA或RNA的构建块）的过程，来自朝日Kasei生物过程（AKB）的创新，THESYS™ACS ERGO合成柱，将于5月14日至17日在波士顿海恩斯会议中心举行的TIDES USA 2024的213号展位上展出和演示。

This new synthesis column offers drastically reduced changeover time between batches while maintaining user safety and product quality..

这个新的合成柱大大缩短了批次之间的转换时间，同时保持了用户安全和产品质量。。

Following the success of AKB’s DAC ERGO™, a liquid chromatography column, the company has continued advancing column technology with the THESYS™ ACS ERGO. The THESYS ACS ERGO is designed for oligonucleotide synthesis and includes an operator-friendly design to facilitate a smooth and safe changeover between runs.

继AKB的DAC ERGO™液相色谱柱取得成功后，该公司继续推进THESYS™ACS ERGO柱技术。THESYS ACS ERGO是为寡核苷酸合成而设计的，包括一个操作友好的设计，以促进运行之间的平稳和安全转换。

It provides the same reliable high-performance as AKB’s other synthesis columns but is uniquely engineered to reduce inefficiencies between batches – with upwards of an hour of time savings as well as projected labor reduction..

它提供了与AKB其他合成塔相同的可靠高性能，但经过独特设计，可减少批次之间的低效率，节省了一个小时以上的时间，并预计将减少劳动力。。

The time-saving features of the THESYS™ ACS ERGO are achieved by eliminating the use of threaded bolts in the changeover and maintenance process, which can be tedious and time-consuming to remove between runs. AKB has ergonomically designed the THESYS™ ACS ERGO for faster changeover without cost to safety, which improves customer efficiency while maintaining operator safety and product reliability..

THESYS™ACS ERGO的省时功能是通过在转换和维护过程中不使用螺纹螺栓来实现的，而在两次运行之间删除螺纹螺栓既繁琐又耗时。AKB根据人体工程学原理设计了THESYS™ACS ERGO，可以在不增加安全成本的情况下实现更快的转换，从而提高了客户效率，同时保持了操作员的安全性和产品的可靠性。。

“Our new, bolt-free design is unique to the column market and makes unpacking and cleaning far less time-consuming,” said Chris Rombach, EVP at Asahi Kasei Bioprocess America (AKBA). “Every feature of the ACS ERGO has been considered, with greater productivity for manufacturers and operator safety as the top priorities.”.

旭化成生物处理美国公司（AKBA）执行副总裁克里斯·罗姆巴赫（ChrisRombach）表示：“我们的新型无螺栓设计是色谱柱市场所独有的，可以大大减少拆箱和清洁的时间。”。“ACS ERGO的每一项功能都得到了考虑，提高制造商的生产力和操作员的安全性是首要任务。”。

THESYS™ ACS includes an innovative I-bar format that makes removing the top of the column more efficient and a unique frame with an integrated gearbox and wheel to facilitate smooth, safe unpacking and cleaning. Furthermore, the column has a minimized footprint to seamlessly integrate into the manufacturing floor..

THESYS™ACS包括一种创新的I-bar格式，可以更高效地卸下立柱顶部，以及一个独特的框架，该框架带有集成齿轮箱和车轮，便于顺利、安全地拆包和清洁。此外，色谱柱的占地面积最小，可以无缝集成到生产车间中。。

In addition to its booth at the event, AKB will host a ‘Spotlight Presentation’ on May 16 at 12:20 p.m. in room 302 about the oligo manufacturing process. Dr. Tom Krebstakies, Sales Manager for Europe and Asia at AKB, will speak about innovations from synthesis through concentration and the applicable equipment considerations for effective technical implementation..

除了在活动上的展位外，AKB还将于5月16日下午12:20在302房间举办一场关于寡核苷酸制造过程的“聚光灯演示”。AKB欧洲和亚洲销售经理Tom Krebstakies博士将介绍从合成到集中的创新以及有效技术实施的适用设备考虑因素。。

Attendees are invited to visit AKB at Booth 213 to explore new products, witness live demos, and learn more about how AKB’s innovations make manufacturing therapeutics easier.

与会者被邀请参观位于213号展位的AKB，探索新产品，见证现场演示，并进一步了解AKB的创新如何使制造疗法更容易。

Learn more about how AKB helps oligo process engineers quickly improve throughput, efficiency, and costs.

进一步了解AKB如何帮助oligo流程工程师快速提高吞吐量、效率和成本。

About Asahi Kasei Bioprocess

关于旭化成生物工艺

The Fluid Management Business Unit of Asahi Kasei Bioprocess is devoted to solving therapeutic product safety, efficiency, and purity challenges within the pharmaceutical and bioprocessing industries. With technology platforms for oligonucleotide synthesis, buffer formulation, chromatography, and filtration, our bioprocess systems, columns, and automation solutions advance GMP manufacturing of critical drug substances around the world.

旭化成生物工艺的流体管理业务部门致力于解决制药和生物加工行业中治疗产品的安全性，效率和纯度挑战。凭借寡核苷酸合成、缓冲液配制、色谱和过滤的技术平台，我们的生物过程系统、色谱柱和自动化解决方案推动了全球关键药物的GMP生产。

Built with pride, built with quality, built to exceed expectations. “Built for You.” For more information, please visit https://fluidmgmt.ak-bio.com..

骄傲而生，品质而生，超越期望而生。“专为您打造。”有关更多信息，请访问https://fluidmgmt.ak-bio.com..

About Asahi Kasei

关于旭化成

The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber business, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 48,000 employees worldwide, the company contributes to sustainable society by providing solutions to the world’s challenges through its three business sectors of Material, Homes, and Health Care.

旭化成集团为全世界人民的生活做出了贡献。自1922年成立氨和纤维素纤维业务以来，旭化成一直通过积极的业务组合转型来满足各个年龄段不断发展的需求。该公司在全球拥有48000多名员工，通过其材料、住房和医疗保健三个业务部门为世界挑战提供解决方案，为可持续社会做出了贡献。

For more information, visit www.asahi-kasei.com..

欲了解更多信息，请访问www.asahi-kasei.com。。

Asahi Kasei is also dedicated to sustainability initiatives and is contributing to reaching a carbon neutral society by 2050. To learn more, visit https://www.asahi-kasei.com/sustainability/.

旭化成还致力于可持续发展倡议，并为到2050年实现碳中和社会做出贡献。要了解更多信息，请访问https://www.asahi-kasei.com/sustainability/.